Parkinson's disease is a progressive neurodegenerative disorder that impacts the central nervous system. 

Its characteristic motor symptoms arise from the depletion of dopamine, a vital neurotransmitter. 

This depletion is linked to the death of a specific group of cells located deep within the brain, in an area known as the substantia nigra. 

While the precise reason for this cell death remains unknown, its impact on dopamine levels is central to the disease.

The hallmark motor deficits of Parkinson's include slowed physical movement (bradykinesia), muscle rigidity, involuntary resting tremors, postural instability, and gait disturbances. 

These symptoms stem from abnormal functioning of the basal ganglia, a collection of deep brain structures responsible for controlling the automatic and precise aspects of movement without conscious effort. 

Normally, neurons in the basal ganglia release dopamine, which is crucial for motor control. 

In Parkinson's disease, either the release of dopamine or the function of its receptors is compromised.

As the disease advances, motor difficulties often extend to controlling speech and swallowing. 

Speech may become slow and soft, sometimes reducing to little more than a whisper as patients struggle to force air through their windpipes, necessary for vocal projection.

Parkinson's disease affects an estimated 1-2% of the global population, with approximately 1 million patients in the U.S. alone.

In Israel, although there isn't a centralized registry, estimates based on prevalence suggest between 60,000 and 100,000 patients. 

The average age of onset for Parkinson's is around 57-58 years, and its prevalence increases with age.

Various drug therapies are available that aim to alleviate Parkinson's symptoms by artificially introducing dopamine into the body or mimicking its effects. 

While these can ease symptoms, they often come with side effects such as nausea (especially at the beginning of treatment), involuntary movements (dyskinesia), confusion, or hallucinations resulting from an overdose. 

Other medications, like Selegiline, may slow disease progression if taken in early stages, while drugs such as Amantadine stimulate dopamine release from neurons but can cause confusion. 

Medications like Bromocriptine replace dopamine by activating its receptors. 

Sunny Skies Healthcare ™  offers an effective, safe, and non-invasive treatment for Parkinson's Disease using Deep Transcranial Magnetic Stimulation (Deep TMS™). 

This therapy involves magnetic stimulation of specific brain structures and networks linked to Parkinson's, leading to significant improvement for patients.

The procedure is an outpatient treatment, meaning it doesn't require hospitalization or anesthesia. 

It is generally well-tolerated and comes with minimal systemic side effects.

Sunny Skies Healthcare ™ Deep TMS Treatment for Parkinson's Disease is approved by the CE and ANIVISA.

You are viewing a page that is not intended for persons in the United States, and includes information about treatment applications that HAVE NOT BEEN CLEARED by the FDA for safety and efficacy.

However, BrainsWay Deep TMS™ has received the European CE Mark for the treatment of many conditions.

This significant approval underscores the therapy's established safety and efficacy for these indications in Europe. While regulatory statuses vary by region, this CE Mark highlights the recognized potential of Deep TMS as a therapeutic option for:

Major Depressive Disorder (MDD)

Anxiety Depression

Obsessive-Compulsive Disorder (OCD)

Smoking Cessation

Alzheimer's Disease (AD)

Autism

Bipolar Disorder

Chronic Pain

Multiple Sclerosis (MS)

Parkinson's Disease

Post-Stroke Rehabilitation

Post-Traumatic Stress Disorder (PTSD)

Negative Symptoms of Schizophrenia